Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Colorectal cancer (CRC), the third most common type of cancer, is the second leading cause
of cancer-related mortality rates worldwide. Although modern research was able to shed …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world.
It is a heterogeneous disease, which can be classified into different subtypes, characterized …

Colorectal cancer (CRC) is the third most common malignancy worldwide. Surgery remains
the most important treatment for non-metastatic CRC, and the administration of adjuvant …

Simple Summary The BRAFV600E mutation accounts for 8–10% of metastatic colorectal
cancer (mCRC) patients and it is an established prognostic factor. Median overall survival of …

Objective Cancer stem cells are responsible for tumour spreading and relapse. Human
epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in …

Notwithstanding recent treatment advances in metastatic colorectal cancer (mCRC),
chemotherapy with a combination of a fluoropyrimidine and a folate agent, often 5 …

Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC);
however, many tumours are unresponsive or develop resistance. We performed genomic …